Welcome to our dedicated page for RAFINA INNOVATIONS news (Ticker: VICA), a resource for investors and traders seeking the latest updates and insights on RAFINA INNOVATIONS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RAFINA INNOVATIONS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RAFINA INNOVATIONS's position in the market.
OPTEC International, Inc. (OTC: OPTI) has acquired a controlling interest in Rafina Innovations (OTC: VICA) to drive global expansion. Rafina focuses on advanced medical technology, holding multiple patents, and recently acquired C-Pharm Ltd, reporting over $1.7 million in revenues for Q1 2021. This acquisition will enhance OPTEC’s reach in the pharmaceutical sector, particularly with major shipping lines. The collaboration aims to bolster sales and shareholder value while introducing OPTEC's Z2O technology to pandemic-hit regions.
Rafina Innovations (OTC PINK: VICA) reported Q1 2021 revenues of $1.7 million, a significant increase from $700,000 in Q1 2020. The company attributes this growth to new business strategies and geographical expansion amidst the pandemic. CEO highlighted the opportunity to introduce additional products to C-Pharm's existing customer base and expand into Europe-Asia markets. Rafina focuses on innovative solutions in prosthetics, orthotics, and diabetes, positioning itself for robust growth with a strong pipeline of technologies.
Rafina Innovations Inc. (OTC PINK: VICA) reported C-Pharm's 2020 sales at $2.7 million, with expectations to exceed this in 2021. The company plans to expand distribution channels across Cyprus, Greece, and Euro-Asia markets. This growth strategy includes leveraging C-Pharm's existing customer base to introduce more products, positioning Rafina as a key player in the medical supply sector.
The acquisition of C-Pharm is seen as a strategic advantage for Rafina, aiming to enhance its global reach in the medical and pharmaceutical industry.
Rafina Innovations (OTC PINK: VICA) has officially launched its new website, which aims to enhance user experience and accessibility to company information. Additionally, Rafina has secured an Exclusive Distribution Agreement with OPTEC International, Inc. for the distribution of their PPE products in Cyprus. This partnership is expected to boost sales and revenue streams. The company is focused on growth in prosthetics and rehabilitation markets, leveraging advanced technologies to maintain high margins.
Rafina Innovations (OTC PINK: VICA) announced the 100% acquisition of C-PHARM Ltd, a licensed wholesale pharmaceutical company operating in Euro-Asia. C-PHARM holds a wholesale license for medicinal products, facilitating import and export of Active Pharmaceutical Ingredients (API). Rafina plans to increase funding for C-PHARM to expand operations and reduce costs by 10-20%. The acquisition aims to extend C-PHARM's client base beyond Greece, enhancing market opportunities. A new website reflecting these changes is set to launch soon.
FAQ
What is the market cap of RAFINA INNOVATIONS (VICA)?
